According to the results of this trial, IL-1 inhibition was not an effective analgesic/antiinflammatory treatment in most patients with knee OA and associated synovitis, based on the limited improvement in WOMAC pain scores and lack of synovitis improvement with lutikizumab. The gene discussed is IL1A; the disease is synovitis.